Provectus is a clinical-stage biotechnology company focused on developing immunotherapy medicines based on small molecules known as halogenated xanthenes, of which the company owns the entire class. In Provectus, the lead molecule is called "Rose Bengal Disodium." Clinical and non-clinical data suggest that Provectus' drug platform may be used to treat a variety of diseases, including oncology, dermatology, hematology, virology, microbiology, and ophthalmology.

Provecctus is a rare disorder that affects the bones. It often starts with pain in the bones and muscles, but can turn into more serious health problems like fractures or even cancer.

Provectus is a term commonly used to describe advancement, progress, or forward development. It originates from Latin and broadly refers to growth driven by improvement, innovation, or learning. In modern usage, Provectus is often adopted as a name by organisations, projects, or platforms that focus on transformation and performance enhancement. Depending on the context, it may relate to technology development, data-driven decision making, business optimisation, or strategic growth initiatives. The core idea behind Provectus remains consistent: moving systems, skills, or processes toward a more advanced state. When used in professional or commercial settings, the term signals an emphasis on efficiency, scalability, and long-term improvement rather than short-term gains. Overall, Provectus represents a mindset centred on structured progress, continuous refinement, and building sustainable value over time.